How will yervoy's patent expiration affect market competition?

How will Yervoy's patent expiration affect market competition

Yervoy (ipilimumab) faces patent expiration on December 27, 2023. The primary compound patent covering the drug itself has already expired, leaving secondary patents on formulations and manufacturing methods that keep generic or biosimilar versions from entering the market easily.

Why are companies challenging this patent?

Several biosimilar developers have filed IPR petitions against the remaining patents. IPR challenges seek to invalidate claims on manufacturing processes and formulation stability that Bristol-Myers Squibb still holds. Companies like Celltrion and Samsung Bioepis have been active in this space for checkpoint inhibitors.

Can biosimilars enter before patent expiry?

No. The remaining formulation and method-of-use patents block at-risk launches. Companies must wait until those patents expire or receive a district court ruling that clears the way for a biosimilar launch. At-risk launches are rare for complex biologics such as Yervoy.

How does this drug compare with Keytruda?

Yervoy works as a CTLA-4 inhibitor, while Keytruda is a PD-1 inhibitor. Both belong to immune checkpoint inhibitors, but they serve different roles in combination therapies. Yervoy is most commonly used with Opdivo (nivolumab) in melanoma and renal cell carcinoma. Keytruda has broader approvals and higher sales.

When does exclusivity expire?

The secondary patents on formulations and methods extend exclusivity through 2031 in some territories. Pediatric exclusivity and regulatory data protection may add further time. Timeframes vary by country.

What side effects are patients asking about?

Patients report immune-related adverse events such as colitis, hepatitis, and endocrinopathies. These occurs at higher rates in Yervoy monotherapy and when combined with Opdivo. The company continues to monitor long-term safety data.

Who makes Yervoy?

Bristol-Myers Squibb holds the sole producer rights until patents clear. Potential biosimilar entrants include Celltrion, Samsung Bioepis, and other Korean and European firms.

What is the pricing difference between current price and biosimilars?

Current price is approximately $6,500 per 50 mg vial. Biosimilar price discounts are expected to reach 20-30% once launched. Price reduction signals will first appear in Europe and then spread to the America.